Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 13CNS 3Lymphoid 2Gastrointestinal 2Plasma cell 1Other 1Breast 1

Conditions

Brain Neoplasms 2Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasm Metastasis 1Meningioma 1Lung Neoplasms 1Ependymoma 1

Interventions

Temozolomide 400Radiotherapy 239Bevacizumab 185Magnetic Resonance Spectroscopy 168Radiosurgery 142Cyclophosphamide 95Irinotecan 79Carboplatin 79Etoposide 78Radiation 76pembrolizumab 70Nivolumab 59Surgical Procedures, Operative 57Filgrastim 56Specimen Handling 53Cisplatin 50Blood Specimen Collection 46Topotecan 45Vincristine 43Melphalan 38Radiotherapy, Intensity-Modulated 36Pemetrexed 36Ipilimumab 36Lomustine 35Everolimus 35Magnetic Resonance Imaging 34Erlotinib Hydrochloride 34Drug Therapy 34Surveys and Questionnaires 33sargramostim 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × brigatinib × CNS × Clear all
NCT04374305 2026-05-06

INTUITT-NF2

Massachusetts General Hospital

Phase 2 Recruiting
109 enrolled
CNS

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

NCT04634110 2022-10-24

Brigatinib Before Brain Irradiation Trial (B3i Trial)

University of Colorado, Denver

Phase 2 Terminated
1 enrolled 6 charts
CNSThoracic

Brain Neoplasms, Lung Neoplasms

NCT03868423 2022-02-18

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

Ohio State University Comprehensive Cancer Center

Phase 2 Withdrawn
CNS

Brain Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡